Table 3 Mechanistic insights into HMGB1 in heart failure and remodelling (detrimental effects)

From: Scoping review of preclinical and clinical studies on the role of HMGB1 in heart disease

Authors (Year)

Study population (Model)

Time of interventions (in vivo route)

Agonist HMGB1 (Supplier)

Antagonist HMGB1

Receptors and Pathways

Lin et al. (2016)102

NRCMsa; WT & RAGE−/− mice (TAC)

–

rHMGB1 (Sigma-Aldrich)b

–

RAGE

Su et al. (2021)100

NMCMsa

–

rHMGB1 (Sigma-Aldrich)b

–

14-3-3η/PI3K/Akt/NFAT3

Zhang et al. (2016)42

NRCMs (Mechanical stress); C57Bl/6J mice (TAC)

Before TAC (i.m.c.)

rHMGB1 (HMGBiotech)c

Box-A

–

Zhang et al. (2019)101

H9c2 cells & NRCMs (Mechanical stress)

–

rHMGB1 (HMGBiotech)b,c

–

RAGE; ERK1/2

Zhang et al. (2020)43

C57Bl/6J mice (TAC)

Before TAC (i.m.c.)

rHMGB1 (HMGBiotech)c

–

–

Zhang et al. (2022)38

Patients (HFpEF); C57Bl/6mice (HFpEF)

1 day post TAC (i.p.)

–

Glycyrrhizin

–

  1. aCo-culture with rHMGB1 without additional injury.
  2. bIn vitro assay only.
  3. cHMGBiotech specifies the redox forms of HMGB1 on their website. However, these studies did not include the catalogue number or specify the redox forms used.
Back to article page